RLYB - Rallybio Corporation Stock Price, Fair Value and News

1.83USD-0.07 (-3.68%)Market Closed

Market Summary

USD1.83-0.07

Market Closed

-3.68%

RLYB Stock Price

View Fullscreen

RLYB RSI Chart

RLYB Valuation

Market Cap

69.2M

Price/Earnings (Trailing)

-0.93

Price/Sales (Trailing)

12.33

EV/EBITDA

-0.62

Price/Free Cashflow

-1.15

RLYB Price/Sales (Trailing)

RLYB Profitability

EBT Margin

-1292.75%

Return on Equity

-70.22%

Return on Assets

-64.49%

Free Cashflow Yield

-87.11%

RLYB Fundamentals

RLYB Revenue

Revenue (TTM)

5.6M

Rev. Growth (Yr)

35.2%

Rev. Growth (Qtr)

-6.28%

RLYB Earnings

Earnings (TTM)

-74.6M

Earnings Growth (Yr)

-24.93%

Earnings Growth (Qtr)

-10.17%

Breaking Down RLYB Revenue

Last 7 days

10.9%

Last 30 days

7.0%

Last 90 days

39.7%

Trailing 12 Months

-66.1%

How does RLYB drawdown profile look like?

RLYB Financial Health

Current Ratio

12.39

RLYB Investor Care

Shares Dilution (1Y)

17.98%

Diluted EPS (TTM)

-1.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.4M	0	4.7M	5.6M
2022	134.0K	391.0K	904.0K	2.0M
2021	141.8K	112.5K	83.3K	54.0K
2020	0	0	0	171.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Rallybio Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2023	lieber jonathan i	bought	26,050	5.21	5,000	see remarks
Mar 07, 2023	5am partners v, llc	sold	-820,000	8.2	-100,000	-
Mar 07, 2023	parmar kush	sold	-820,000	8.2	-100,000	-
Jun 03, 2022	5am opportunities i, l.p.	sold	-629,112	12.5	-50,329	-
Jun 03, 2022	5am opportunities i, l.p.	sold	-1,245,890	12.5	-99,671	-
Jun 03, 2022	parmar kush	sold	-629,112	12.5	-50,329	-
Jun 03, 2022	parmar kush	sold	-1,245,890	12.5	-99,671	-
May 23, 2022	5am opportunities i, l.p.	sold	-436,189	13.00	-33,553	-
May 23, 2022	5am opportunities i, l.p.	sold	-863,811	13.00	-66,447	-
May 23, 2022	parmar kush	sold	-436,189	13.00	-33,553	-

Which funds bought or sold RLYB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CAPSTONE INVESTMENT ADVISORS, LLC	added	9.00	-3,735	20,165	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	9.00	9.00	-%
Apr 25, 2024	Bank of New York Mellon Corp	added	0.04	-48,680	167,084	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-74.53	-4,000	1,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-57,219	-	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	-	-	-%
Apr 05, 2024	Canaan Partners XI LLC	unchanged	-	-1,112,240	3,810,470	4.20%
Mar 11, 2024	VANGUARD GROUP INC	added	1.35	-995,042	2,542,890	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	162	42,061	90,906	-%

Are Funds Buying or Selling RLYB?

Are funds buying RLYB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RLYB

No. of Funds

Unveiling Rallybio Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	viking global investors lp	11.1%	4,194,777	SC 13G/A
Feb 12, 2024	pivotal bioventure partners fund i, l.p.	6.4%	2,404,644	SC 13D/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 02, 2024	novo holdings a/s	4.7%	1,767,861	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 06, 2023	new leaf ventures iii, l.p.	5.8%	2,147,757	SC 13G/A
Feb 01, 2023	canaan xi l.p.	6.4%	2,059,712	SC 13G/A
Jan 23, 2023	tekla capital management llc	4.6%	1,727,067	SC 13G/A
Nov 17, 2022	novo holdings a/s	6.2%	2,296,007	SC 13G
Jun 07, 2022	5am ventures v, l.p.	7.7%	2,478,969	SC 13D/A

Recent SEC filings of Rallybio Corporation

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	D	D
Apr 11, 2024	DEF 14A	DEF 14A
Apr 10, 2024	8-K	Current Report
Mar 13, 2024	S-8	Employee Benefits Plan
Mar 12, 2024	8-K	Current Report
Mar 12, 2024	10-K	Annual Report
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading

Peers (Alternatives to Rallybio Corporation)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Rallybio Corporation News

Latest updates

Rallybio Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-6.3%	1,448,000	1,545,000	1,546,000	1,071,000	525,000	270,000	97,000	12,000	12,000	13,000	17,000	29,500	42,000	47,000
Operating Expenses	9.0%	21,112,000	19,363,000	18,374,000	17,091,000	18,860,000	17,615,000	14,318,000	12,313,000	9,981,000	10,530,000	12,824,000	-	6,710,000	4,662,000
S&GA Expenses	-14.6%	5,188,000	6,075,000	7,172,000	6,298,000	6,750,000	7,477,000	6,670,000	6,219,000	5,021,000	3,712,000	3,787,000	-	1,580,000	1,570,000
R&D Expenses	19.8%	15,924,000	13,288,000	11,202,000	10,793,000	12,110,000	10,138,000	7,648,000	6,094,000	4,960,000	6,818,000	9,037,000	-	5,130,000	3,092,000
EBITDA Margin	12.0%	-12.90	-14.66	-19.95	-33.32	-68.16	-136	-348	-840	-298	-220	-175	-145	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	10,000	-	13,000	12,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-10.7%	-19,629,000	-17,726,000	-16,755,000	-15,989,000	-18,237,000	-17,245,000	-14,108,000	-12,192,000	-9,864,000	-10,659,000	-12,793,000	-	-6,629,000	-4,558,000
EBT Margin	12.0%	-12.93	-14.70	-20.00	-33.41	-68.34	-136	-349	-842	-299	-221	-175	-145	-	-
Net Income	-10.2%	-20,242,000	-18,374,000	-17,318,000	-16,203,000	-18,370,000	-17,583,000	-14,498,000	-12,415,000	-10,196,000	-11,127,000	-13,275,000	-	-7,155,000	-4,893,000
Net Income Margin	11.7%	-13.29	-15.05	-20.36	-33.96	-69.54	-139	-359	-870	-317	-235	-186	-154	-	-
Free Cashflow	29.2%	-11,657,000	-16,471,000	-18,765,000	-15,264,000	-14,739,000	-13,568,000	-13,767,000	-10,023,000	-11,002,000	-12,850,000	-11,991,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-13.2%	116	133	148	162	180	144	156	169	182	194	120	142
Current Assets	-13.3%	115	132	147	161	179	142	154	168	181	192	118	141
Cash Equivalents	27.9%	24.00	19.00	33.00	40.00	57.00	52.00	61.00	81.00	175	187	113	140
Net PPE	-12.8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00
Liabilities	-1.8%	9.00	10.00	8.00	7.00	11.00	12.00	8.00	6.00	7.00	7.00	7.00	6.00
Current Liabilities	-1.5%	9.00	9.00	8.00	7.00	11.00	11.00	7.00	6.00	7.00	7.00	7.00	6.00
Shareholder's Equity	-14.1%	106	124	139	155	169	132	148	163	176	186	113	136
Retained Earnings	-9.4%	-235	-215	-196	-178	-160	-144	-126	-108	-94.03	-81.61	-71.42	-47.01
Additional Paid-In Capital	0.8%	341	339	336	333	330	277	274	272	270	268	-	183
Shares Outstanding	0.1%	38.00	38.00	38.00	38.00	38.00	31.00	30.00	30.00	32.00	28.00	23.00	23.00
Float	-	-	-	134	-	-	-	121	-	108	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	29.3%	-11,645	-16,471	-13,384	-18,765	-15,264	-14,735	-13,554	-13,731	-9,886	-10,872	-12,846	-11,929	-	-	-
Share Based Compensation	-3.2%	2,549	2,634	2,692	3,045	2,294	2,504	2,647	2,054	1,529	1,055	539	522	-	-	-
Cashflow From Investing	450.8%	16,909	3,070	6,214	1,465	-30,646	5,772	-7,118	-80,178	-137	-130	-1,504	-562	-	-	-
Cashflow From Financing	-	72.00	-	210	-139	51,157	-79.00	-	-	-1,621	85,251	-663	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RLYB Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 53,544	$ 40,689
General and administrative	25,388	27,195
Total operating expenses	78,932	67,884
Loss from operations	(78,932)	(67,884)
Other income:
Interest income	6,147	1,963
Other income	262	342
Total other income, net	6,409	2,305
Loss before equity in losses of joint venture	(72,523)	(65,579)
Loss on investment in joint venture	2,041	1,075
Net loss	$ (74,564)	$ (66,654)
Net loss per common share, basic (in dollars per share)	$ (1.84)	$ (2.09)
Net loss per common share, diluted (in dollars per share)	$ (1.84)	$ (2.09)
Weighted-average common shares outstanding, basic (in shares)	40,447,388	31,821,311
Weighted-average common shares outstanding, diluted (in shares)	40,447,388	31,821,311
Other comprehensive gain (loss):
Net unrealized gain (loss) on marketable securities	$ 229	$ (214)
Other comprehensive gain (loss)	229	(214)
Comprehensive loss	$ (74,335)	$ (66,868)

RLYB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 24,494	$ 56,958
Marketable securities	85,435	112,036
Prepaid expenses and other assets	4,860	10,502
Total current assets	114,789	179,496
Property and equipment, net	246	385
Operating lease right-of-use assets	346	524
Investment in joint venture	239	30
Total assets	115,620	180,435
Current liabilities:
Accounts payable	976	1,114
Accrued expenses	8,068	9,449
Operating lease liabilities	219	181
Total current liabilities	9,263	10,744
Operating lease liabilities, noncurrent	173	374
Total liabilities	9,436	11,118
Commitments and contingencies (Note 10)
Stockholders' equity
Common stock, $0.0001 par value per share; 200,000,000 shares authorized as of December 31, 2023 and 2022, respectively; and 37,829,565 and 37,837,369 shares issued and outstanding as of December 31, 2023 and 2022, respectively	4	4
Preferred stock, $0.0001 par value per share; 50,000,000 shares authorized as of December 31, 2023 and 2022, respectively; no shares issued or outstanding as of December 31, 2023 and 2022, respectively	0	0
Additional paid-in capital	341,410	330,208
Accumulated other comprehensive gain (loss)	15	(214)
Accumulated deficit	(235,245)	(160,681)
Total stockholders' equity	106,184	169,317
Total liabilities and stockholders' equity	$ 115,620	$ 180,435

About Rallybio Corporation

Rallybio Corporation, a clinical-stage biotechnology company, engages in identifying, accelerating, and development of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

CEO	Dr. Stephen Uden M.B, M.D.
WEBSITE	rallybio.com
INDUSTRY	Biotechnology
EMPLOYEES	45

Rallybio Corporation Frequently Asked Questions

What is the ticker symbol for Rallybio Corporation? What does RLYB stand for in stocks?

RLYB is the stock ticker symbol of Rallybio Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rallybio Corporation (RLYB)?

As of Thu May 02 2024, market cap of Rallybio Corporation is 69.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RLYB stock?

You can check RLYB's fair value in chart for subscribers.

What is the fair value of RLYB stock?

You can check RLYB's fair value in chart for subscribers. The fair value of Rallybio Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rallybio Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RLYB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rallybio Corporation a good stock to buy?

The fair value guage provides a quick view whether RLYB is over valued or under valued. Whether Rallybio Corporation is cheap or expensive depends on the assumptions which impact Rallybio Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RLYB.

What is Rallybio Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, RLYB's PE ratio (Price to Earnings) is -0.93 and Price to Sales (PS) ratio is 12.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RLYB PE ratio will change depending on the future growth rate expectations of investors.